Manuel Haschke

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 9

Top Topics

Venous Thromboembolism

Cross Sectional

Top Venues

British journal of clinical pharmacology

International journal of analytical chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Manuel Haschke
Food-derived compounds for CYP-phenotyping. British journal of clinical pharmacology 90 (3) (2024)
Elias Bekka, Samuel E Christen, Laura Hermann, Aristomenis K Exadaktylos, Manuel Haschke, Evangelia Liakoni
Residents' Knowledge regarding Recreational Drug Screening Immunoassays at a Swiss Hospital Group. International journal of analytical chemistry 2024 (2024)
Manuel Haschke
Food-derived compounds for CYP-phenotyping. British journal of clinical pharmacology 90 (3) (2024)
Elias Bekka, Samuel E Christen, Laura Hermann, Aristomenis K Exadaktylos, Manuel Haschke, Evangelia Liakoni
Residents' Knowledge regarding Recreational Drug Screening Immunoassays at a Swiss Hospital Group. International journal of analytical chemistry 2024 (2024)
Manuel Haschke
Food-derived compounds for CYP-phenotyping. British journal of clinical pharmacology (2024)
Elias Bekka, Samuel E Christen, Laura Hermann, Aristomenis K Exadaktylos, Manuel Haschke, Evangelia Liakoni
Residents' Knowledge regarding Recreational Drug Screening Immunoassays at a Swiss Hospital Group. International journal of analytical chemistry 2024 (2024)
Manuel Haschke
Food-derived compounds for CYP-phenotyping. British journal of clinical pharmacology 90 (3) (2024)
Elias Bekka, Samuel E Christen, Laura Hermann, Aristomenis K Exadaktylos, Manuel Haschke, Evangelia Liakoni
Residents' Knowledge regarding Recreational Drug Screening Immunoassays at a Swiss Hospital Group. International journal of analytical chemistry 2024 (2024)
Irene Scholz, Evangelia Liakoni, Felix Hammann, Katharina Elisabeth Grafinger, Urs Duthaler, Michael Nagler, Stephan Krähenbühl, Manuel Haschke
Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. British journal of clinical pharmacology 87 (3) (2020)